| Name | Title | Contact Details |
|---|
At PopHealthCare, we believe healthcare should be personal. For us, that means bringing care to those who need it most, where they will be able to achieve their health goals best–at home or wherever they reside. Using in-home assessments and cutting-edge analytics, we identify high-risk patients and partner with health plans to keep them out of the hospital with our care team of compassionate, smart, deeply committed healthcare providers available 24/7. This commitment and integrity expands to all areas of our business. With over 22 clients in 17 states, PopHealthCare offers a fully integrated approach to care delivery, risk adjustment and quality enhancements, serving the highest risk populations with unwavering dedication. Our risk adjustment solutions include not only risk adjustment, but also chart retrievals and analytics and reporting, to help you effectively manage your risk adjustment program. Our goal is to facilitate risk score accuracy and help clients plan for the future with more precision, leveraging our unique combination of technology, in-depth industry expertise, and concierge-level service. Emcara Health, PopHealthCare`s value-based national medical group that does house calls for vulnerable populations, delivers personalized, attentive care either as the Primary Care Provider (PCP) or in collaboration with a patient`s community-based PCP. PopHealthcare`s success in spearheading the transformation of in-home care enables Emcara Health to deliver industry-leading outcomes in patient experience, care quality, cost of care, health equity, and employee satisfaction. As part of the GuideWell family of companies, we are working hard every day to improve the delivery of care through new innovative models that provide superior health outcomes for patients and our partners.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
Salon 01 is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Go-Girl is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
nTELAGENT, Inc is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.